Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lamotrigine: first experience in Italy]

F de Romanis1, N Sopranzi

  • 1Dipartimento di Scieze Neurologiche, Università degli Studi di Roma La Sapienza.

La Clinica Terapeutica
|March 1, 1995
PubMed
Summary

Lamotrigine (LTG) is a novel antiepileptic drug demonstrating efficacy as add-on therapy for refractory partial seizures. This study found LTG to be safe and effective, with reversible side effects and a significant reduction in seizure frequency for most patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A sharp band resonance absorption filter.

Applied optics·2010
Same author

[Lamotrigine in the therapy of resistant epilepsy].

La Clinica terapeutica·1999
Same author

[Efficacy of vigabatrin associated with carbamazepine in the treatment of epilepsy. Follow up 1993-1996].

La Clinica terapeutica·1998
Same author

[Lamotrigine: monotherapy in refractory epilepsy].

La Clinica terapeutica·1997
Same author

[Felbamate: a long-term study in subjects with refractory epilepsy].

La Clinica terapeutica·1997
Same author

[New antiepileptic drugs: a review and personal contribution].

La Clinica terapeutica·1996

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Lamotrigine (LTG) is a novel antiepileptic agent.
  • It is chemically distinct from existing antiepileptic drugs.
  • Refractory partial seizures present a significant treatment challenge.

Purpose of the Study:

  • To evaluate the safety and efficacy of lamotrigine (LTG) as adjunctive therapy.
  • To assess LTG's effectiveness in patients with refractory partial complex and/or partial secondary generalized seizures.
  • To compare LTG add-on therapy against a placebo control.

Main Methods:

  • A placebo-controlled study involving 34 patients with refractory partial seizures.
  • Lamotrigine (LTG) was administered as add-on therapy alongside carbamazepine (CBZ).
  • Dosage of LTG averaged 564.5 +/- 74.4 mg/day.

Main Results:

  • A reduction in total seizure count was observed in 61.4% of patients.
  • The incidence of adverse effects associated with LTG was low.
  • Observed side effects were reversible.
  • LTG demonstrated a long half-life and did not interact with other antiepileptic drugs (AEDs).

Conclusions:

  • Lamotrigine (LTG) is an effective antiepileptic drug (AED) for treating therapy-resistant partial seizures.
  • LTG offers an easily manageable addition to existing treatment regimens.
  • The drug exhibits a favorable safety profile with reversible adverse effects.

Related Experiment Videos